# Traumacel FAM Trium in the Post-market Surveillance Phase

> **NCT05177874** · NA · COMPLETED · sponsor: **Bioster, a.s.** · enrollment: 98 (actual)

## Conditions studied

- Bleeding
- Surgical Wound

## Interventions

- **DEVICE:** Traumacel FAM Trium
- **DEVICE:** Surgicel Fibrillar

## Key facts

- **NCT ID:** NCT05177874
- **Lead sponsor:** Bioster, a.s.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-18
- **Primary completion:** 2021-01-02
- **Final completion:** 2021-01-02
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2022-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177874, "Traumacel FAM Trium in the Post-market Surveillance Phase". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05177874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*